Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.49 |
| ▸ | FLT3 | P36888 | 2/20 | 0.49 |
| ▸ | AURKA | O14965 | 2/20 | 0.49 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.49 |
| ▸ | PLK4 | O00444 | 1/20 | 0.49 |
| ▸ | STK25 | O00506 | 1/20 | 0.49 |
| ▸ | CIT | O14578 | 1/20 | 0.49 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.49 |
| ▸ | IKBKB | O14920 | 1/20 | 0.49 |
| ▸ | GAK | O14976 | 1/20 | 0.49 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.49 |
| ▸ | CHUK | O15111 | 1/20 | 0.49 |
| ▸ | MUSK | O15146 | 1/20 | 0.49 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.49 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.49 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1597595 | 1.00 | KDR (0.49) | KDRMAPK8CHEK1FGFR1FLT3 | |
| SCHEMBL1596900 | 0.91 | KDR (0.50) | KDRMAPK8CHEK1FGFR1FLT3 | |
| SCHEMBL1596895 | 0.91 | KDR (0.50) | KDRMAPK8CHEK1FGFR1FLT3 | |
| SCHEMBL1598023 | 0.88 | KDR (0.49) | KDRMAPK8CHEK1FGFR1FLT3 | |
| SCHEMBL1598026 | 0.88 | KDR (0.49) | KDRMAPK8CHEK1FGFR1FLT3 | |
| SCHEMBL1595912 | 0.87 | KDR (0.50) | KDRMAPK8CHEK1FGFR1FLT3 | |
| SCHEMBL1595914 | 0.87 | KDR (0.50) | KDRMAPK8CHEK1FGFR1FLT3 | |
| SCHEMBL1597000 | 0.86 | MAPK8 (0.58) | KDRMAPK8CHEK1FGFR1FLT3 | |
| SCHEMBL1596997 | 0.86 | MAPK8 (0.58) | KDRMAPK8CHEK1FGFR1FLT3 | |
| SCHEMBL27626373 | 0.85 | KDR (0.53) | KDRMAPK8CHEK1FGFR1FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919517-B2 | Indazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-04-05 | — | — | US | disclosed |
| US-20090082348-A1 | INDAZOLE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| US-7470717-B2 | Indazole derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-12-30 | — | — | US | disclosed |
| CN-100390149-C | Indazole derivatives | KYOWA HAKKO KOGYO KK (JP) | 2008-05-28 | — | — | CN | disclosed |
| US-20070117856-A1 | Indazole derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-24 | — | — | US | disclosed |
| CN-1777590-A | Indazole derivatives | KYOWA HAKKO KOGYO KK (JP) | 2006-05-24 | — | — | CN | disclosed |
| EP-1652842-A1 | INDAZOLE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117856-A1 | Indazole derivatives | IGF1R, NR0B2, ADRA2B | KDR 383/4885MAPK8 2117/4885CHEK1 2191/4885 |
| US-20090082348-A1 | INDAZOLE DERIVATIVES | IGF1R, NR0B2, ADRA2B | KDR 383/4885MAPK8 2117/4885CHEK1 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.